StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Neurocrine Bio. (NBIX) PT Raised to $145 at Piper Sandler Due to Ingrezza Long-Term Potential
August 4, 2020 9:10 AM
Piper Sandler analyst David Amsellem raised the price target on Neurocrine Bio. (NASDAQ: NBIX) to $145.00 (from $141.00) while maintaining ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Analyst EPS View
Analyst PT Change
Next Articles
Neurocrine Bio. (NBIX) PT Lowered to $146 at Morgan Stanley
August 4, 2020 7:51 AM
Neurocrine Bio. (NBIX) PT Raised to $142 at Jefferies
August 4, 2020 6:21 AM
Neurocrine Bio. (NBIX) PT Raised to $140 at H.C. Wainwright
August 4, 2020 6:14 AM
Neurocrine Bio. (NBIX) PT Lowered to $126 at Credit Suisse
August 4, 2020 6:13 AM
Neurocrine Bio. (NBIX) PT Raised to $136 at RBC Capital
August 4, 2020 6:10 AM
Neurocrine Bio. (NBIX) PT Raised to $145 at Stifel
August 4, 2020 5:22 AM
Neurocrine Bio. (NBIX) PT Raised to $120 at SVB Leerink
August 4, 2020 5:04 AM
Neurocrine Bio. (NBIX) PT Raised to $127 at Barclays
August 4, 2020 4:20 AM
UPDATE: JPMorgan Downgrades Neurocrine Bio. (NBIX) to Neutral
August 4, 2020 4:17 AM
Neurocrine Biosciences (NBIX) Tops Q2 EPS by 69c, Revenues Beat
August 3, 2020 4:42 PM
Neurocrine Biosciences Reports Second Quarter 2020 Financial Results
August 3, 2020 4:01 PM
